

Therese SÄ,rlie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5265170/publications.pdf>

Version: 2024-02-01

74
papers

25,112
citations

109321

35
h-index

85541

71
g-index

78
all docs

78
docs citations

78
times ranked

23177
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer. <i>NAR Cancer</i> , 2022, 4, zcac008.	3.1	6
2	Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion. <i>International Journal of Cancer</i> , 2021, 149, 1247-1256.	5.1	5
3	Multi-Omics Marker Analysis Enables Early Prediction of Breast Tumor Progression. <i>Frontiers in Genetics</i> , 2021, 12, 670749.	2.3	9
4	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx [®] Digital Spatial Profiler. <i>Cancers</i> , 2021, 13, 4456.	3.7	50
5	Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 6118.	3.7	10
6	GLI1-induced mammary gland tumours are transplantable and maintain major molecular features. <i>International Journal of Cancer</i> , 2020, 146, 1125-1138.	5.1	5
7	AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. <i>IScience</i> , 2020, 23, 101649.	4.1	20
8	Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer. <i>Cancer Reports</i> , 2020, 3, e1248.	1.4	5
9	Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions. <i>Npj Breast Cancer</i> , 2020, 6, 26.	5.2	24
10	The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers. <i>Scientific Reports</i> , 2020, 10, 1277.	3.3	22
11	Re-definition of claudin-low as a breast cancer phenotype. <i>Nature Communications</i> , 2020, 11, 1787.	12.8	108
12	Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers. <i>Breast Cancer Research</i> , 2019, 21, 85.	5.0	18
13	A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 163-175.	2.7	3
14	A Bayesian two-way latent structure model for genomic data integration reveals few pan-genomic cluster subtypes in a breast cancer cohort. <i>Bioinformatics</i> , 2019, 35, 4886-4897.	4.1	9
15	An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. <i>Nature Communications</i> , 2019, 10, 5499.	12.8	132
16	Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials. <i>Acta Oncologica</i> , 2018, 57, 38-43.	1.8	22
17	The tankyrase inhibitor G007-LK inhibits small intestine LGR5+ stem cell proliferation without altering tissue morphology. <i>Biological Research</i> , 2018, 51, 3.	3.4	27
18	Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. <i>Breast Cancer Research</i> , 2017, 19, 120.	5.0	93

#	ARTICLE	IF	CITATIONS
19	Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. <i>Cell Reports</i> , 2016, 16, 1166-1179.	6.4	85
20	The Impact of Gene Expression Patterns in Breast Cancer. <i>Clinical Chemistry</i> , 2016, 62, 1150-1151.	3.2	13
21	A conditional transgenic mouse line for targeted expression of the stem cell marker LGR5. <i>Developmental Biology</i> , 2015, 404, 35-48.	2.0	9
22	Glycan-related gene expression signatures in breast cancer subtypes; relation to survival. <i>Molecular Oncology</i> , 2015, 9, 861-876.	4.6	47
23	The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. <i>BMC Cancer</i> , 2015, 15, 468.	2.6	44
24	From autonomy to community; new perspectives on tumorigenicity and therapy resistance. <i>Cancer Treatment Reviews</i> , 2015, 41, 809-813.	7.7	2
25	Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort. <i>Clinical Cancer Research</i> , 2014, 20, 5272-5280.	7.0	80
26	Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. <i>Acta Oncologica</i> , 2014, 53, 1337-1346.	1.8	34
27	Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. <i>British Journal of Surgery</i> , 2014, 101, 925-938.	0.3	34
28	Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. <i>BMC Cancer</i> , 2014, 14, 211.	2.6	34
29	Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. <i>Breast Cancer Research</i> , 2014, 16, R5.	5.0	45
30	Differential In Vivo Tumorigenicity of Distinct Subpopulations from a Luminal-Like Breast Cancer Xenograft. <i>PLoS ONE</i> , 2014, 9, e113278.	2.5	6
31	Mutation Screening of the TP53 Gene by Temporal Temperature Gel Electrophoresis (TTGE). <i>Methods in Molecular Biology</i> , 2014, 1105, 315-324.	0.9	1
32	Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 775-786.	2.8	11
33	Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. <i>Molecular Oncology</i> , 2013, 7, 130-142.	4.6	26
34	Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. <i>Molecular Oncology</i> , 2013, 7, 704-718.	4.6	77
35	Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. <i>BMC Cancer</i> , 2013, 13, 512.	2.6	61
36	Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2802-2807.	7.1	149

#	ARTICLE	IF	CITATIONS
37	Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6124-6129.	7.1	96
38	Ischemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue. Molecular Oncology, 2011, 5, 564-576.	4.6	29
39	How to personalise treatment in early breast cancer. European Journal of Cancer, 2011, 47, S310-S311.	2.8	4
40	Combining Gene Signatures Improves Prediction of Breast Cancer Survival. PLoS ONE, 2011, 6, e17845.	2.5	38
41	Merging transcriptomics and metabolomics - advances in breast cancer profiling. BMC Cancer, 2010, 10, 628.	2.6	101
42	In Silico Ascription of Gene Expression Differences to Tumor and Stromal Cells in a Model to Study Impact on Breast Cancer Outcome. PLoS ONE, 2010, 5, e14002.	2.5	23
43	Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients. Science Translational Medicine, 2010, 2, 38ra47.	12.4	138
44	Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Molecular Oncology, 2010, 4, 98-118.	4.6	147
45	Corrigendum to "Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer" [Mol. Oncol. 1 (2007) 160-171]. Molecular Oncology, 2010, 4, 169-169.	4.6	0
46	Triple-negative breast cancer: Present challenges and new perspectives. Molecular Oncology, 2010, 4, 209-229.	4.6	252
47	On the molecular biology of breast cancer. Molecular Oncology, 2010, 4, 171-173.	4.6	8
48	Molecular diversity in ductal carcinoma <i>in situ</i> (DCIS) and early invasive breast cancer. Molecular Oncology, 2010, 4, 357-368.	4.6	107
49	Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma <i>in situ</i> and early invasive breast cancer. Breast Cancer Research, 2010, 12, R3.	5.0	128
50	The importance of gene-centring microarray data. Lancet Oncology, The, 2010, 11, 719-720.	10.7	42
51	Introducing Molecular Subtyping of Breast Cancer Into the Clinic?. Journal of Clinical Oncology, 2009, 27, 1153-1154.	1.6	43
52	Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. BMC Medical Genomics, 2009, 2, 26.	1.5	8
53	Full sequencing of TP53 identifies identical mutations within <i>in situ</i> and invasive components in breast cancer suggesting clonal evolution. Molecular Oncology, 2009, 3, 214-219.	4.6	26
54	Molecular profiling and characterization of luminal-like and basal-like <i>in vivo</i> breast cancer xenograft models. Molecular Oncology, 2009, 3, 469-482.	4.6	96

#	ARTICLE	IF	CITATIONS
55	Pathway based analysis of SNPs with relevance to 5â€FU therapy: Relation to intratumoral mRNA expression and survival. <i>International Journal of Cancer</i> , 2008, 123, 577-585.	5.1	20
56	Molecular Classification of Breast Tumors: Toward Improved Diagnostics and Treatments. , 2007, 360, 91-114.		63
57	Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. <i>Molecular Oncology</i> , 2007, 1, 160-171.	4.6	128
58	Evaluation of MetriGenix custom 4Dâ„¢ arrays applied for detection of breast cancer subtypes. <i>BMC Cancer</i> , 2006, 6, 59.	2.6	7
59	Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. <i>BMC Genomics</i> , 2006, 7, 127.	2.8	314
60	Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and geneâ€™expression subtypes of breast cancer. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 1033-1040.	2.8	464
61	Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2914-2918.	4.1	114
62	Genetic variation in putative regulatory loci controlling gene expression in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7735-7740.	7.1	32
63	Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3738-3743.	7.1	934
64	Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 95, 105-111.	2.5	16
65	Genomics in breast cancerâ€™therapeutic implications. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 26-33.	4.3	53
66	NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer. <i>Analytical Cellular Pathology</i> , 2005, 27, 169-173.	1.4	7
67	Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer. <i>Cancer Research</i> , 2004, 64, 4218-4226.	0.9	321
68	Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. <i>European Journal of Cancer</i> , 2004, 40, 2667-2675.	2.8	336
69	Repeated observation of breast tumor subtypes in independent gene expression data sets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8418-8423.	7.1	4,849
70	Gene Expression Patterns in Ovarian Carcinomas. <i>Molecular Biology of the Cell</i> , 2003, 14, 4376-4386.	2.1	302
71	Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12963-12968.	7.1	1,098
72	Molecular portraits of human breast tumours. <i>Nature</i> , 2000, 406, 747-752.	27.8	13,397

#	ARTICLE	IF	CITATIONS
73	Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases. <i>Breast Cancer Research and Treatment</i> , 1998, 48, 259-264.	2.5	20
74	Screening for p53 Gene Mutations in Archived Tumors of Workers Occupationally Exposed to Carcinogens: Examples from Analysis of Bladder Tumors. <i>Journal of Occupational and Environmental Medicine</i> , 1995, 37, 59-68.	1.7	23